Glenmark Pharmaceuticals surges on plan to initiate clinical study for GBR 1342

16 May 2017 Evaluate

Glenmark Pharmaceuticals is currently trading at Rs. 718.05, up by 1.80 points or 0.25% from its previous closing of Rs. 716.25 on the BSE.

The scrip opened at Rs. 722.90 and has touched a high and low of Rs. 730.00 and Rs. 715.20 respectively. So far 156944 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 993.00 on 01-Nov-2016 and a 52 week low of Rs. 709.00 on 15-May-2017.

Last one week high and low of the scrip stood at Rs. 930.00 and Rs. 709.00 respectively. The current market cap of the company is Rs. 20327.59 crore.

The promoters holding in the company stood at 46.50%, while institutions and non-institutions held 40.80% and 12.70% respectively.

Glenmark Pharmaceuticals, a global pharmaceutical company will initiate clinical study for GBR 1342. The US Food and Drug Administration (USFDA) cleared the company’s Investigational New Drug (IND) application to initiate a Phase 1 study of GBR 1342, a humanized, bispecific monoclonal antibody (bsAb) being studied for the treatment of multiple myeloma in patients who have received prior therapies.

GBR 1342 is designed to activate the patient’s immune system by redirecting immune cells towards tumor tissue, which may lead to targeted destruction of tumors. It is based on Glenmark’s proprietary BEAT (Bispecific Engagement by Antibodies based on the T cell receptor) technology platform.

The first-in-human Phase 1 study of GBR 1342 will enroll subjects with multiple myeloma who have exhausted available therapies.

 

Glenmark Pharma Share Price

1986.75 -5.95 (-0.30%)
29-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1589.30
Dr. Reddys Lab 1208.45
Cipla 1320.35
Zydus Lifesciences 890.20
Lupin 2131.80
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×